OZEMvsSBIOETF Comparison
VS
Roundhill GLP-1 & Weight Loss ETF (OZEM) and ALPS Medical Breakthroughs ETF (SBIO) belong to the same industry segment: Tomorrow's Treatments. Both ETFs have the same top 3 sector exposures: and Healthcare. OZEM is more expensive with a Total Expense Ratio (TER) of 0.59%, versus 0.5% for SBIO. OZEM is down -4.17% year-to-date (YTD) with +$22M in YTD flows. SBIO performs better with 24.68% YTD performance, and +$41M in YTD flows. Run a side-by-side ETF comparison of OZEM and SBIO below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
OZEM vs SBIO performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/28/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | OZEM SBIO | +0.15%-0.90% | +6.60%+19.27% | -4.17%+24.68% | +24.59%+92.66% | n/a+109.07% | n/a+44.84% |
| Flows | OZEM SBIO | +$10M+$17M | +$9M+$23M | +$22M+$41M | +$22M+$51M | -+$20M | --$24M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | OZEM SBIO | +21.48%+35.26% | +22.70%+30.57% | n/a+30.92% | n/a+33.91% |
| Max drawdown | OZEM SBIO | -6.63%-10.73% | -19.51%-12.63% | n/a-42.12% | n/a-52.50% |
| Max drawdown duration | OZEM SBIO | 51d43d | 183d60d | n/a331d | n/a1479d |
Trading data
OZEM | SBIO | |
Last sale 7/29/2026 at 1:30 PM | $32.66 | $63.14 |
| Previous close 07/28/2026 | $32.81 | $63.52 |
| Consolidated volume 07/28/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
OZEM
is actively managed and doesn’t replicate an indexOZEM | SBIO | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/29/2026 at 1:30 PM
Live
Closed
OZEM | SBIO | |
|---|---|---|
| Last price | $32.66 | $63.14 |
| 1D performance | -0.46% | -0.60% |
| AuM | $63.07 M | $202.41 M |
| E/R | 0.59% | 0.5% |
Characteristics
OZEM | SBIO | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Roundhill Investments | ALPS |
| Benchmark | - | S-Network Medical Breakthroughs Index |
| N° of holdings | 24 | 103 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | May 21, 2024 | December 30, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
OZEM
USA
44.42%
Denmark
19.13%
China
16.37%
Other
20.08%
SBIO
USA
88.02%
Other
11.98%
Sectors
OZEM
Healthcare
99.56%
Other
0.44%
SBIO
Healthcare
99.06%
Other
0.94%
Diversification
OZEM
Total weight of top 15 holdings out of 15
82.24%
SBIO
Total weight of top 15 holdings out of 15
40.08%
Top 15 holdings
Data as of June 30, 2026
OZEM
Novo Nordisk A/S
13.29%
Eli Lilly & Co.
13.07%
Pfizer Inc.
6.58%
Kailera Therapeutics, Inc.
6.00%
Viking Therapeutics, Inc.
5.84%
CSPC Pharmaceutical Group Ltd.
5.22%
Chugai Pharmaceutical Co., Ltd.
4.53%
Ascletis Pharma, Inc.
3.95%
Zealand Pharma A/S
3.93%
AstraZeneca PLC
3.89%
Amgen, Inc.
3.89%
Hanmi Pharmaceutical Co., Ltd.
3.33%
Roche Holding AG
3.12%
Structure Therapeutics, Inc.
2.89%
MBX Biosciences, Inc.
2.71%
SBIO
Apogee Therapeutics, Inc.
4.36%
CG Oncology, Inc.
3.33%
Xenon Pharmaceuticals, Inc.
3.09%
Oruka Therapeutics, Inc.
3.05%
Dianthus Therapeutics, Inc.
2.83%
Travere Therapeutics, Inc.
2.80%
Definium Therapeutics, Inc.
2.73%
Veradermics, Inc.
2.72%
Edgewise Therapeutics, Inc.
2.32%
ACADIA Pharmaceuticals, Inc.
2.30%
Denali Therapeutics, Inc.
2.17%
Relay Therapeutics, Inc.
2.17%
NewAmsterdam Pharma Co. NV
2.10%
Crinetics Pharmaceuticals, Inc.
2.09%
Structure Therapeutics, Inc.
2.02%
Frequently asked questions about OZEM and SBIO
How have the OZEM and SBIO ETFs performed in 2026?
As of July 28, 2026, OZEM is down -4.17% year-to-date (YTD), while SBIO has returned 24.68%. That puts SBIO better performer ahead so far this year.
Which ETF is attracting more investor money: OZEM or SBIO?
Year-to-date, the OZEM ETF saw +$22M in flows, compared to +$41M for SBIO.
Which ETF is more volatile: OZEM or SBIO?
Over the past year, OZEM had a volatility of 22.7%, while SBIO experienced 30.57%.
Which ETF is bigger: OZEM or SBIO?
As of July 28, 2026, OZEM holds $63.07 M in assets under management (AUM), while SBIO manages $202.41 M.
What sectors do the OZEM and SBIO ETFs invest in?
OZEM leans toward sectors like Healthcare. Meanwhile, SBIO focuses on Healthcare.
What are the top holdings of the OZEM ETF and SBIO ETF?
OZEM top holdings include Novo Nordisk A/S, Eli Lilly & Co. and Pfizer Inc.. SBIO holds in its top three: Apogee Therapeutics, Inc., CG Oncology, Inc. and Xenon Pharmaceuticals, Inc..
Which ETF is more diversified: OZEM or SBIO?
OZEM holds 24 securities with 82.24% of its assets in the top 15. SBIO has 104 securities and a top 15 weight of 40.08%.
Advertisement
Latest news about OZEM & SBIO
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Advertisement
Advertisement
